Skip to main content
OpenTrials
Completed

NCT Number: NCT02995460

Interval Training Study in Psoriatic Arthritis

Psoriatic arthritis is a chronical inflammatory disease characterized by pain and reduced physical function. Patients have a higher risk of cardiovascular disease and a higher body mass index.

A pilot study in patients with rheumatoid arthritis has shown positive effect on inflammation after 12 weeks of high-intensity interval training.

The primary aim of this study is to determine whether high-intensity interval training affects the disease activity in psoriatic arthritis. This intervention is believed to result in benefits in terms of inflammation, body composition and risk factors for cardiovascular disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Psoriatic Arthritis Arthritis Arthritis, Psoriatic Bone Diseases Joint Diseases Musculoskeletal Diseases Psoriasis Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases Spinal Diseases Spondylarthritis Spondylarthropathies Spondylitis

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • fulfilling the CASPAR criteria of psoriatic arthritis
  • ability to exercise.

Exclusion criteria

  • Inability to exercise
  • very high disease Activity
  • unstable ischemic cardiovascular disease
  • severe pulmonary disease
  • pregnancy
  • breastfeeding
  • drug- and alcohol addictions

Treatment and study plan

Interval Training

Behavioral

4x4 high intensity interval training

Primary outcomes

  1. Patient global assesment (PGA)

    Time frame: Baseline, 3 months (right after intervention), 9 months

    PGA is measured as a change between timepoints. PGA is registered by the patient on a visual analog scale.

  2. Maximal oxygen uptake (VO2 max)

    Time frame: Baseline, 3 months (right after intervention), 9 months

    The VO2 max is measured as a change between timepoints

Secondary outcomes

  1. Total lean mass

    Time frame: Baseline, 3 months (right after intervention), 9 months

    Total lean mass is measured as a change between timepoints and is measured by dual energy x-ray absorptiometry (DXA).

  2. Total body fat

    Time frame: Baseline, 3 months (right after intervention), 9 months

    Total body fat is measured as a change between timepoints and is measured by dual energy x-ray absorptiometry (DXA).

Sponsors and collaborators

Lead sponsor

Norwegian University of Science and Technology

Other

Collaborators

  • Helse Midt-Norge

Registry information

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Dec 16, 2016
Registry last updated
Nov 13, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.